Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Approves Bayer AG's Drug For Rare Gastrointestinal Tract Cancer-Reuters


Monday, 25 Feb 2013 03:25pm EST 

Reuters reported that The U.S. Food and Drug Administration said it has approved Bayer AG's drug Stivarga for the treatment of a rare type of gastrointestinal tract cancer. Bayer and Onyx will jointly market Stivarga in the United States. Bayer will market it alone in the rest of the world. Stivarga is a pill that works by blocking several enzymes that promote cancer growth. 

Company Quote

134.31
-0.17 -0.13%
3:15pm EDT